Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Disease × Bevacizumab × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 230 Carcinoma, Non-Small-Cell Lung 132 Breast Neoplasms 121 Ovarian Neoplasms 86 Glioblastoma 86 Carcinoma, Hepatocellular 68 Rectal Neoplasms 64 Brain Neoplasms 57 Lung Neoplasms 55 Neoplasm Metastasis 54 Neoplasms 52 Colonic Neoplasms 50 Fallopian Tube Neoplasms 43 Glioma 40 Carcinoma, Renal Cell 35 Gliosarcoma 34 Melanoma 26 Adenocarcinoma of Lung 26 Pancreatic Neoplasms 23 Liver Neoplasms 23 Uterine Cervical Neoplasms 21 Stomach Neoplasms 21 Recurrence 20 Triple Negative Breast Neoplasms 18 Kidney Neoplasms 16 Endometrial Neoplasms 16 Esophageal Neoplasms 15 Astrocytoma 14 Carcinoma, Ovarian Epithelial 13 Adenocarcinoma, Bronchiolo-Alveolar 13

Interventions

Prednisone 3 pembrolizumab 2 Melphalan 2 Cytarabine 2 venetoclax 1 ofatumumab 1 obinutuzumab 1 ioflupane 1 ibrutinib 1 gossypol acetic acid 1 gilteritinib 1 fluorocholine 1 fluciclovine F-18 1 deltacortene 1 daratumumab 1 aflibercept 1 abiraterone 1 Temozolomide 1 Self-Management 1 Quality of Life 1 Professional Autonomy 1 Paclitaxel 1 Oncolytic Virotherapy 1 Octreotide 1 Mitoxantrone 1 Methylene Blue 1 Lenalidomide 1 Gemtuzumab 1 Gemcitabine 1 Food 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07134101 2025-08-29

SMARTi-RC01

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting

Gastrointestinal

Disease, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡